Biotech Values

[DewDiligence]

GTCB:

Although I owned a lot already, I added a little more this week. If someone wants to give the shares away, I’ll take them.

Possible near-term news flow:

1. A partnership for ATryn. Guidance was originally for the past summer, but obviously this has slipped.

2. Submission of the answers to the EMEA’s ATryn questions. Guidance is for Q4 (the current quarter). If the submission is accompanied by at least sketchy disclosure of the questions themselves, it could provide a clue on the likelihood and timing of approval.

3. A surprise development with respect to one of GTCB’s "back burner" projects such as Antegren.

--
GTCB has two investor webcasts this month: BIO Emerging Company tomorrow, and Rodman & Renchaw on 10/26. Caution: GTCB is high-risk and high-reward.